In HCC (hepatocellular carcinoma), the analyses of public databases indicate that RAPGEF1 mRNA levels gradually increase in HCC patient samples during HCC progression up to stage III, which is associated with a reduced overall patient survival [56,57]. Here, RAPGEF1 is linked to hepatocellular carcinoma.